Pdgfrβ-Cre小鼠是一种用于研究血管平滑肌细胞和周细胞功能的基因工程小鼠品系。这些小鼠在Pdgfrβ(血小板衍生生长因子受体β)基因的控制下表达Cre重组酶。Pdgfrβ基因主要在血管平滑肌细胞和周细胞中表达,因此Pdgfrβ-Cre小鼠特别适用于在这些细胞类型中引入基因修饰。 Pdgfrβ-Cre小鼠的特点: 1. Cre-LoxP系统: Pdgfrβ...
Crenolanib is a tyrosine kinase inhibitor targeting PDGFR-伪, PDGFR-尾 and Fms related tyrosine kinase-3 (FLT3) that is currently evaluated in several clinical trials. Although platelet-derived growth factor receptor (PDGFR) signalling pathway is believed to play an important role in angiogenesis ...
CP868596 (Crenolanib) is an orally-available, benzimidazole-based inhibitor of PDGFRa and PDGFRb with IC50 values of 0.9 and 1.8 nM, respectively. Fu | CP-868569, CP 868596, CP868569, Crenolanib , 670220-88-9, PDGFR, Kinase
Crenolanib 纯度: 99.28% 产品编号 T2677 别名CP-868596, ARO 002Cas号 670220-88-9 Crenolanib (ARO 002) 是一种口服生物可利用的 III 型酪氨酸激酶抑制剂,抑制 FLT3和 PDGFRα/β的 IC50分别为 4、11和 3.2 nM。 规格价格库存数量 2 mg ¥ 464 现货 5 mg ¥ 698 现货 10 mg ¥ 1,198 ...
Crenolanib (CP-868596)是一种有效的，选择性的PDGFRα/β抑制剂，K为2.1 nM/3.2 nM，也有效抑制FLT3，对D842V突变型而不是V561D突变型敏感，作用于PDGFR比作用于c-Kit， VEGFR-2， TIE-2， FGFR-2， EGFR， erbB2，和Src选择性高100倍以上。实验操作来自于公开的文献，仅供参考 细胞实验 细胞系...
Crenolanib(CP-868596;ARO 002)是一种可口服的、有效的、选择性的III型酪氨酸激酶PDGFRα/β、FLT3抑制剂,其IC50值分别是11 nM、3.2 nM和4 nM。Crenolanib在CHO细胞中选择性抑制PDGFRα/β,其Kd值分别为2.1 nM和3.2 nM。 产品性质 英文别名(English Synonym) ...
Crenolanib is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR
Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncotargets Ther 7, 1761-1768.Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits...
Generation and characterization of PDGFRα-GFPCreERt2knock-In mouse linePDGFRCreER(T2)knock-inmesodermneural crestmesenchymePlatelet-derived growth factor (PDGF) and its recedoi:10.1002/dvg.22853MiwaKumamotoHiroyukiKumamotoEraKumamotoTakumiKumamotoGenesis: the journal of genetics and development...
The present invention includes methods for treating a PDGFR伪 mutated proliferative disorder in a subject relapsed/refractory to prior tyrosine kinase inhibitor therapy comprising administering to the subject a therapeutically effective of crenolanib,; ;wherein the subject is relapsed/refractory to prior ...